Skip to main content

Advertisement

Table 3 Incidence of selected vaccine-related adverse events by a history of herpes zoster

From: Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study

Adverse events Healthy adults Patients with underlying illnesses Patients with malignancy Patients with diabetes mellitus Patients with autoimmune diseases Patients with chronic renal diseases
No. of events No. of subjects (%)
(95% CI)
No. of events No. of subjects (%)
(95% CI)
No. of events No. of subjects (%)
(95% CI)
No. of events No. of subjects (%)
(95% CI)
No. of events No. of subjects (%)
(95% CI)
No. of events No. of subjects (%)
(95% CI)
Subjects with HZ history N = 155 N = 49 N = 11 N = 28 N = 1 N = 9
 Vaccine-related AEs 198 87 (56%) (48–64%)* 54 23 (47%) (33–62%) 8 4 (36%) (11–69%) 30 13 (46%) (28–66%) 6 1 (100%) 10 5 (56%) (21–86%)
 Injection-site AEs 189 82 (53%) (45–61%)* 54 23 (47%) (33–62%) 8 4 (36%) (11–69%) 30 13 (46%) (28–66%) 6 1 (100%) 10 5 (56%) (21–86%)
 Systemic AEs 9 8 (5%) (2–10%) 0 0 (0%) 0 0 (0%) 0 0 (0%) 0 0 (0%) 0 0 (0%)
Subjects without HZ history N = 1045 N = 251 N = 38 N = 152 N = 9 N = 52
 Vaccine-related AEs 1164 422 (40%) (37–43%) 274 102 (41%) (35–47%) 36 16 (42%) (26–59%) 167 60 (39%) (32–48%) 8 4 (44%) (14–79%) 63 22 (42%) (29–57%)
 Injection-site AEs 1117 409 (39%) (36–42%) 260 95 (38%) (32–44%) 33 14 (37%) (22–54%) 161 58 (38%) (30–46%) 6 3 (33%) (7–70%) 60 20 (38%) (25–53%)
 Systemic AEs 47 38 (4%) (3–5%) 14 11 (4%) (2–8%) 3 2 (5%) (0.6–18%) 6 5 (3%) (1–8%) 2 1 (11%) (0.3–48%) 3 3 (6%) (1–16%)
  1. AE Adverse event, HZ Herpes zoster
  2. *P < 0.05, **P < 0.1 (compared with the proportion of reported subjects without HZ history within the category of subjects)